In 2012 Lindsey completed her studies in Biomedical sciences at the Radboud University in Nijmegen, and graduated with majors in Occupational and Environmental Health and in Toxicology. In august 2012 she started her PhD at the Radboud university medical center, in which she studied the molecular mechanisms underlying (un)wanted transporter mediated drug-drug interactions and assessed the pharmacokinetics and drug-related adverse events of TB drugs as part of multiple drug therapy in TB patients. For the pharmacokinetic studies she spent considerable time at Universitas Padjadjaran and Hasan Sadikin hospital in Bandung, Indonesia, an important partner in tuberculosis research for the Radboudumc. During her PhD Lindsey also completed the training required for the register of professional toxicologists by the Netherlands Society of Toxicology (NVT). After finishing her PhD, in January 2017, Lindsey is continuing her work as a postdoctoral researcher, studying potential new and safe drug regimens against tuberculous meningitis. Furthermore starting from March 2017, she is working as project manager on PanACEA-II, focusing on HIGHRIF1, trial and consortium coordination, drug management, pharmacology, and providing scientific support.
Ilesh Jani is a project investigator at PanACEA II and oversees the project activities in Mozambique. Since 2009, he is the Director General of the Instituto Nacional de Saúde (INS) at Mozambique’s Ministry of Health. Dr. Jani has been a researcher at the INS since 1998, where he also served as the Head of the Department of Immunology from 2004 to 2009.
Ilesh Jani qualified as a medical doctor at the Eduardo Mondlane University in Mozambique. He received a Ph.D. in immunology from the University of London in the United Kingdom. During his career Dr. Jani has lead efforts in the areas of research, public health, education and diagnostics with the objective of strengthening the health system in Mozambique. His research interests include vaccines and diagnostics, including the deployment of these health technologies in resource-limited health systems. Dr. Jani has authored over 50 publications in peer-reviewed scientific journals.
Dr. Jani is currently a member of the executive board of the International Association of National Public Health Institutes (IANPHI), a member of WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and a member of the Program Committee of the Conference on Retroviruses and Opportunistic Infections (CROI).
Derek Sloan is a Senior Clinical Lecturer and Consultant Physician in Infectious Diseases at the University of St Andrews. He studied Immunology and Medicine at the University of Glasgow and worked as a junior doctor in Scotland prior to departing for Chogoria Hospital, Kenya and Hlabisa Hospital, KwaZulu Natal, South Africa in 2004-6, where he worked as a clinician with a specialist interest in HIV and tuberculosis. He returned to the UK to complete specialist training in Infectious Diseases at the Liverpool School of Tropical Medicine. From 2008-12 he completed a Wellcome Trust PhD fellowship on the Clinical Pharmacology of TB treatment in Blantyre, Malawi where he also served as a Consultant Physician in the College of Medicine. He currently serves on the British Thoracic Society MDR-TB Advisory Panel and is engaged in several clinical TB research projects in Europe, Africa and Asia.
Dr Marriott Nliwasa is a final year PhD student with the London School of Hygiene and Tropical Medicine. His PhD covers strategies to reduce risk of early death among adults with symptoms suggestive of tuberculosis (TB): i.e. increasing access to HIV testing, TB screening in communities and health facilities, evaluation of new TB diagnostic tests (Xpert MTB/RIF and TB-LAMP) and their impact on patient outcomes. Marriott’s immediate future research focuses on trials of other new TB tests including Xpert MTB/RIF Ultra, digital chest radiography, IRISA-TB (for TB meningitis). Marriott is also involved in trials of new TB drugs and new TB drug regimens under the EU-Africa PanACEA consortium.
Sébastien Gagneux is Associate Professor of Infection Biology and Head of Department at the Swiss Tropical and Public Health Institute (Swiss TPH)/University of Basel. After receiving his PhD from the University of Basel, he worked as a postdoctoral fellow at Stanford University and at the Institute for Systems Biology in Seattle, USA. He then spent three years as a Program Leader at the MRC National Institute for Medical Research in London, UK before joining Swiss TPH. His research focuses on the ecology and evolution of Mycobacterium tuberculosis, and combines population genomics, molecular epidemiology and experimental approaches to study the effect of bacterial variation on host-pathogen interaction and drug resistance.
Blandina Theophil Mmbaga is a Director of Kilimanjaro Clinical Research Institute at Kilimanjaro Christian Medical Centre in Moshi, Tanzania since 2015 and a Director of the KCMC-Duke University Collaboration Clinical Research site in Moshi since 2013. She also works as a pediatrician at KCMC, Senior Lecturer Kilimanjaro Christian Medical University College (KCMUCo) and Adjunct Ass. Professor of Duke Global Health Institute. Blandina had her undergraduate done at the Nizhny Novgorod State Medical Academy in Russia and Pediatric residence at KCMUCo, Tumaini University. She had her doctorate in public health and epidemiology at the University of Bergen in Norway. She is leading several research activities at KCMC and KCRI mainly in infectious diseases (Tuberculosis, HIV/AIDS, Antimicrobial resistant and zoonoses diseases) as well as maternal and child health.
Blandina has a good experience in leading clinical trials in HIV/AIDS and Tuberculosis under her leadership as IMPAACT scientific and immunology committee member 2006-2012 and IMPAACT site PI since 2013 to date. She has a good experience in students supervision and mentorship both masters and PhD levels within KCMUCo and outside Tanzania (UCT, Glasgow, Bergen University, London School and Duke University) as part co supervision within collaborative research capacity building.
Dr Rassool is a project investigator and project manager for the PanACEA project at the Clinical HIV Research Unit, University of the Witwatersrand Helen Joseph Site.
Dr Rassool holds a medical degree (MBChB) and a diploma in HIV management. He has a long-standing ten year experience in phase II-IV clinical trials. Over the past seven years, Dr Rassool has been managing various projects. He also provides technical and advisory support to the local clinics in the Johannesburg region. He is also lectures medical doctors who attend HIV management courses.
Furthermore, Dr Rassool’s main areas of research are HIV, TB, HIV and TB co-infection as well as other HIV related co-infections (including Kaposi Sarcoma and Hepatitis B). He has 10 publications dealing with HIV and associated conditions.
Nyanda Elias Ntinginya is a leader in all TB studies at NIMR Mbeya Medical Research Centre (NIMR-MMRC) www.nimr-mmrc.org since 2012 and from July 2016 he was appointed the Ag. Centre Director of the same centre. He is the Principal Investigator of PanACEA related studies at NIMR Mbeya Medical Research Centre and therefore oversees activities related to all research initiation, implementation, and coordination at the site.
He is the Medical Doctor and holder of a Master Degree in Tropical and Infectious Diseases from the Liverpool School of Tropical Medicine UK. Recently, Nyanda has successfully defended his PhD at the CIHLMU Centre for International Health at Ludwig-Maximilians- Universität, Munich; Germany. Nyanda has more than 8 years of experience in managing clinical trials, diagnostic and operational studies as a Coordinator, Principal Investigator, Clinical Trial Manager at institutional and national levels in cross-functional and multicultural and international environment. A recognizable experience in research of TB new drugs and diagnostic as well as emerging diseases with a strong expertise on ICH GCP guidelines.
Furthermore, his main area of research interest is on Infectious Diseases in particular TB; ranging from diagnostics, therapeutic to operational/implementation research. He has published particularly with TB, HIV and selected other infectious diseases.
Tim McHugh’s work focuses on respiratory disease with particular emphasis on tuberculosis, with projects that cover the spectrum of activity from transcriptomic analysis of responses to drug treatment through to clinical and operational research in hard to reach communities. The Centre contributes at each end of the anti-tuberculosis drug development pipeline; at one end screening novel compounds for activity and exploring the mechanism of action whilst at the other end of the pipeline providing expertise and infrastructure for the delivery of TB treatment trials. A key element of this work is supporting the development of appropriate laboratory facilities for the handing of high risk pathogens. An important element of his work is capacity development, the Centre provides training for laboratory scientists both on site and in London.
Dr Norbert Heinrich is a board certified paediatrician, who has field work experience in Mchinji District, Malawi. He joined University of Munich in 2008, when the PanACEA consortium was starting up, to become a senior scientist in tuberculosis treatment and diagnostic studies. He acted as sponsor medical expert for the SQ109 EBA and the PanACEA MAMS TB 01 study, and is now coordinating LMU’s team in the PanACEA studies, but also in the AIDA study to validate new diagnostics, under the leadership of Prof. Michael Hölscher. In addition to TB, Dr Heinrich is pursuing research in the field of febrile illness, within the German Center for Infection Research; maintaining the strong partnership that exists between the NIMR-Mbeya Medical Research Centre, and LMU within these networks. To support career development of African scientists in joint projects, Dr Heinrich supervised four PhD students to successful graduation to date.